Related Experiment Video
Updated: May 11, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy
Bradley S Ferguson1, Brooke C Harrison, Mark Y Jeong
1Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.
Insights
Class I histone deacetylase (HDAC) inhibitors suppress cardiac hypertrophy by regulating dual-specificity phosphatase 5 (DUSP5). This mechanism involves a self-reinforcing loop controlling prohypertrophic ERK signaling in heart cells.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Epigenetics
Background:
- Cardiac hypertrophy is a significant risk factor for heart failure morbidity and mortality.
- The precise molecular mechanisms by which histone deacetylase (HDAC) inhibitors suppress cardiac hypertrophy are not fully understood.
Purpose of the Study:
- To elucidate the role of class I HDACs and dual-specificity phosphatase 5 (DUSP5) in regulating cardiac hypertrophy.
- To investigate the signaling pathways involved in HDAC inhibition-mediated suppression of cardiac hypertrophy.
Main Methods:
- Utilized selective class I HDAC inhibitors in cardiac myocytes.
- Investigated the expression and activity of DUSP5 and ERK1/2 signaling pathways.
- Employed ectopic expression of DUSP5 in cardiomyocytes.
Main Results:
- Class I HDACs repress cardiac hypertrophy by inhibiting DUSP5 gene expression.
- DUSP5 acts as a nuclear phosphatase, negatively regulating prohypertrophic ERK1/2 signaling.
- HDAC inhibition of DUSP5 requires MEK activity, establishing a positive feedback loop for ERK signaling.
Conclusions:
- Class I HDACs and DUSP5 are key components of a regulatory circuit controlling cardiac hypertrophy.
- DUSP5 plays a critical role in suppressing agonist-induced cardiac hypertrophy.
- Targeting this HDAC-DUSP5-ERK pathway may offer therapeutic strategies for heart failure.
Abstract:
Cardiac hypertrophy is a strong predictor of morbidity and mortality in patients with heart failure. Small molecule histone deacetylase (HDAC) inhibitors have been shown to suppress cardiac hypertrophy through mechanisms that remain poorly understood. We report that class I HDACs function as signal-dependent repressors of cardiac hypertrophy via inhibition of the gene encoding dual-specificity phosphatase 5 (DUSP5) DUSP5, a nuclear phosphatase that negatively regulates prohypertrophic signaling by ERK1/2. Inhibition of DUSP5 by class I HDACs requires activity of the ERK kinase, mitogen-activated protein kinase kinase (MEK), revealing a self-reinforcing mechanism for promotion of cardiac ERK signaling. In cardiac myocytes treated with highly selective class I HDAC inhibitors, nuclear ERK1/2 signaling is suppressed in a manner that is absolutely dependent on DUSP5. In contrast, cytosolic ERK1/2 activation is maintained under these same conditions. Ectopic expression of DUSP5 in cardiomyocytes results in potent inhibition of agonist-dependent hypertrophy through a mechanism involving suppression of the gene program for hypertrophic growth. These findings define unique roles for class I HDACs and DUSP5 as integral components of a regulatory signaling circuit that controls cardiac hypertrophy.
Related Concept Videos
Regulation of the Unfolded Protein Response
Regulation of Nuclear Protein Sorting
The JAK-STAT Signaling Pathway
Cardiomyopathy III: Hypertrophic Cardiomyopathy
MAPK Signaling Cascades
Abnormal Proliferation
